Stocks · News reference
Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per share from the same
Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today